Liraglutide reduces multiple sclerosis severity in mice by suppressing pro-inflammatory Th1 immune cells
In EAE mice (MS model), liraglutide reduced maximum clinical scores from 2.50 to 1.75 (p=0.005) by decreasing splenic Th1 cell proportions from 11.95% to 5.94% (p=0.025), providing direct evidence of peripheral immunomodulation.
Quick Facts
What This Study Found
Max clinical score: 2.50 (EAE) vs 1.75 (EAE+liraglutide), p=0.005. Th1 cells: 11.95%→5.94% with liraglutide (p=0.025). Treg: no significant change. Body weight: no significant difference. n=10 per treatment group.
Key Numbers
How They Did This
EAE induced in C57BL/6 mice via MOG immunization. 3 groups: control (n=8), EAE (n=10), EAE+liraglutide (n=10). Liraglutide 10 µg/kg SC every other day from day 8. Flow cytometry of splenocytes at day 20.
Why This Research Matters
This provides the first direct evidence that a GLP-1 drug modifies MS-like disease through specific immune cell modulation (Th1 suppression), moving beyond general anti-inflammatory effects to a defined immunological mechanism.
The Bigger Picture
GLP-1 drugs are accumulating evidence for neuroprotection in multiple neurological conditions. This study adds a specific immunological mechanism—Th1 suppression—supporting GLP-1 drug repurposing for autoimmune neurological diseases.
What This Study Doesn't Tell Us
Preliminary study with small groups (n=10). Only splenic T cells analyzed—brain-infiltrating cells not assessed. Treg effect may need longer treatment. EAE is a simplified MS model.
Questions This Raises
- ?Does liraglutide also modify T cell responses within the CNS?
- ?Would higher doses or longer treatment show Treg effects?
- ?Could liraglutide complement existing MS immunotherapies?
Trust & Context
- Key Stat:
- Th1 cells halved Liraglutide reduced pro-inflammatory Th1 cells from 12% to 6% in EAE mice, providing a specific immunological mechanism for its MS disease-modifying effect
- Evidence Grade:
- Preliminary preclinical study with small groups. Clear mechanism identified but needs replication and expansion.
- Study Age:
- Published in 2025.
- Original Title:
- Liraglutide Attenuates Disease Severity in Experimental Autoimmune Encephalomyelitis by Modulating Splenic T Helper Cell Subsets.
- Published In:
- Brain and behavior, 15(11), e71074 (2025)
- Authors:
- Song, Shuang, Li, Bin(7), Guo, Ruoyi, Zhou, Yi, Xue, Yumei, Guo, Li
- Database ID:
- RPEP-13651
Evidence Hierarchy
Frequently Asked Questions
Could a diabetes drug treat multiple sclerosis?
This mouse study shows liraglutide reduced MS-like disease severity by specifically suppressing the pro-inflammatory immune cells (Th1) that attack nerve insulation. While very preliminary, it adds to growing evidence that GLP-1 drugs may have a role in treating autoimmune neurological conditions.
How does liraglutide affect the immune system in MS?
MS is partly driven by overactive Th1 immune cells. In this study, liraglutide halved the proportion of Th1 cells in the spleen, reducing the inflammatory attack on nerve tissue. This is a peripheral immunomodulatory effect—the drug modified immune cell balance outside the brain.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13651APA
Song, Shuang; Li, Bin; Guo, Ruoyi; Zhou, Yi; Xue, Yumei; Guo, Li. (2025). Liraglutide Attenuates Disease Severity in Experimental Autoimmune Encephalomyelitis by Modulating Splenic T Helper Cell Subsets.. Brain and behavior, 15(11), e71074. https://doi.org/10.1002/brb3.71074
MLA
Song, Shuang, et al. "Liraglutide Attenuates Disease Severity in Experimental Autoimmune Encephalomyelitis by Modulating Splenic T Helper Cell Subsets.." Brain and behavior, 2025. https://doi.org/10.1002/brb3.71074
RethinkPeptides
RethinkPeptides Research Database. "Liraglutide Attenuates Disease Severity in Experimental Auto..." RPEP-13651. Retrieved from https://rethinkpeptides.com/research/song-2025-liraglutide-attenuates-disease-severity
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.